Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $20.33

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $20.3333.

ENTA has been the topic of several recent analyst reports. Westpark Capital boosted their price target on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, September 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Friday, January 9th. Jefferies Financial Group upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the stock from $14.00 to $20.00 in a report on Wednesday, October 1st. Finally, JPMorgan Chase & Co. started coverage on shares of Enanta Pharmaceuticals in a research note on Friday, November 14th. They issued an “overweight” rating and a $17.00 price target for the company.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, insider Tara Lynn Kieffer sold 2,106 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $29,968.38. Following the completion of the sale, the insider owned 30,620 shares of the company’s stock, valued at approximately $435,722.60. This trade represents a 6.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jay R. Luly sold 4,743 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $67,492.89. Following the sale, the chief executive officer owned 858,026 shares of the company’s stock, valued at approximately $12,209,709.98. This represents a 0.55% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 11,961 shares of company stock valued at $170,149 in the last three months. Corporate insiders own 13.89% of the company’s stock.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Tudor Investment Corp ET AL bought a new stake in Enanta Pharmaceuticals during the 3rd quarter valued at $125,000. Harvest Investment Services LLC bought a new position in shares of Enanta Pharmaceuticals in the third quarter valued at $146,000. PharVision Advisers LLC acquired a new position in shares of Enanta Pharmaceuticals during the third quarter valued at about $429,000. Quarry LP acquired a new position in shares of Enanta Pharmaceuticals during the third quarter valued at about $81,000. Finally, Public Employees Retirement System of Ohio raised its holdings in shares of Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 1,100 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Trading Up 1.8%

Shares of Enanta Pharmaceuticals stock opened at $12.80 on Friday. The business has a 50-day moving average price of $14.10 and a two-hundred day moving average price of $10.79. Enanta Pharmaceuticals has a 1-year low of $4.09 and a 1-year high of $17.15. The company has a market cap of $369.41 million, a P/E ratio of -3.34 and a beta of 0.95.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, November 17th. The biotechnology company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%.The company had revenue of $15.13 million for the quarter, compared to analyst estimates of $15.60 million. Equities research analysts forecast that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.